Investigational combination of first-in-class bispecific antibodies TALVEY (talquetamab) and TECVAYLI (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease
Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9…
Indian Researchers Call for Balanced and Responsible Research Assessments: Springer Nature Survey Reveals Global Insights
NEW DELHI, June 11, 2025 /PRNewswire/ -- A global survey conducted by…
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma
Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33…
Iovance Announces Five-year Results of Amtagvi (lifileucel) in Patients with Advanced Melanoma at ASCO Annual Meeting
One-time Amtagvi Treatment Demonstrated Durable Responses and a Five-year Overall Survival Rate…
BitMart Research: MCP+AI Agent – New framework for AI applications
Mahe, Seychelles , May 09, 2025 (GLOBE NEWSWIRE) -- BitMart Research, the…
Louis Limited Introduces AI-Powered Financial Insights for Global Market
Louis Limited launches an AI-powered trading app globally that tracks traders' emotional…
Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
Antitumor activity observed with confirmed partial responses in 50% of patientsat highest…
Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis
ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor…
LEO Pharma Presents New Late-Breaking Delgocitinib Cream Data For the Third Consecutive Year at AAD 2025
The post hoc analysis investigated treatment responses in a patient subgroup with…
Agora Launches Conversational AI Engine for Seamless Voice AI Experiences
The new solution allows developers to use any AI model to create…